Oviva Therapeutics Appoints Rachel Rimsky Rubin as Chief Operating Officer
Retrieved on:
Tuesday, September 12, 2023
NEW YORK, Sept. 12, 2023 /PRNewswire/ -- Oviva Therapeutics, a premier biotech company dedicated to addressing the vast unmet need in women's health by developing first-in-class therapeutics to preserve ovarian function and consequently extend female healthspan, today announced the appointment of Rachel Rimsky Rubin as its new Chief Operating Officer (COO), effective as of September 5, 2023.
Key Points:
- NEW YORK, Sept. 12, 2023 /PRNewswire/ -- Oviva Therapeutics, a premier biotech company dedicated to addressing the vast unmet need in women's health by developing first-in-class therapeutics to preserve ovarian function and consequently extend female healthspan, today announced the appointment of Rachel Rimsky Rubin as its new Chief Operating Officer (COO), effective as of September 5, 2023.
- Prior to joining Oviva, Rubin served as Vice President of Investments and Programs at Roivant Social Ventures.
- "We are thrilled to welcome Rachel Rimsky Rubin to the Oviva team as our first Chief Operating Officer," said Daisy Robinton, Co-Founder and CEO of Oviva Therapeutics.
- In her role, Rubin will build infrastructure and implement company strategy to usher Oviva through its next phase of growth.